Bruce Johnson, MD
Family Medicine · Ooltewah, TNNPI 1619954575
Payments from drug & device makers
Across 375 payments — averaging $15.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$803
- Novo Nordisk$723
- AbbVie$430
- GSK$376
- Novartis$281
- AstraZeneca$272
- plus $3K from 32 others
What the payments were for
- Food & beverage$5,650100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 66 | $803 |
| Novo Nordisk | 52 | $723 |
| AbbVie(2 entities) | 24 | $430 |
| GSK | 23 | $376 |
| Novartis | 19 | $281 |
| AstraZeneca | 19 | $272 |
| Astellas Pharma US Inc | 17 | $271 |
| Boehringer Ingelheim | 17 | $261 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $255 |
| Abbott | 13 | $253 |
| Bayer | 14 | $248 |
| Johnson & Johnson | 17 | $243 |
| Lilly USA, LLC | 11 | $144 |
| Amgen | 9 | $128 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $98 |
| Sanofi-aventis U.S. LLC | 6 | $89 |
| E.r. Squibb & Sons, L.L.C. | 6 | $89 |
| Esperion Therapeutics, Inc. | 5 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $67 |
| Amarin Pharma, Inc. | 4 | $66 |
| Otsuka America Pharmaceutical, Inc. | 3 | $61 |
| Jazz Pharmaceuticals Inc. | 3 | $57 |
| Eisai Inc. | 3 | $45 |
| Nevro Corp. | 2 | $38 |
| Medtronic(2 entities) | 2 | $37 |
| Inspire Medical Systems, Inc. | 1 | $33 |
| Merck | 2 | $26 |
| Seqirus USA Inc | 1 | $20 |
| Evoke Pharma, Inc. | 1 | $19 |
| Alkermes, Inc. | 1 | $19 |
| Boston Scientific | 1 | $18 |
| Antares Pharma, Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Mylan Specialty L.p. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $13 |
How this compares
$5,664 in reported general payments places this provider in the 80th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 78 | $85,349 |
| MounjaroTirzepatide | 39 | $39,531 |
| RybelsusSemaglutide | 28 | $35,251 |
| EliquisApixaban | 43 | $26,340 |
| Nurtec OdtRimegepant Sulfate | 26 | $24,309 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $23,050 |
| XareltoRivaroxaban | 25 | $19,882 |
| JanuviaSitagliptin Phosphate | 20 | $19,264 |
| TrulicityDulaglutide | 16 | $15,191 |
| JardianceEmpagliflozin | 21 | $14,649 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $14,023 |
| LinzessLinaclotide | 18 | $11,134 |
| MyrbetriqMirabegron | 21 | $10,580 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $8,985 |
| MovantikNaloxegol Oxalate | 17 | $8,953 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $723 | $120,600106 claims |
| Lilly USA, LLCMounjaro, Trulicity | $144 | $54,72155 claims |
| PfizerEliquis, Nurtec Odt | $803 | $50,64869 claims |
| MerckJanuvia, Lagevrio (Eua) | $26 | $28,11532 claims |
| GSKTrelegy Ellipta | $376 | $23,05036 claims |
| Johnson & JohnsonXarelto | $243 | $19,88225 claims |
| Boehringer IngelheimJardiance | $261 | $14,64921 claims |
| AbbVieLinzess, Synthroid | $430 | $13,34248 claims |
| Astellas Pharma US IncMyrbetriq | $271 | $10,58021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Ooltewah
- Kent GrotefendtOoltewah$17K
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.